Skip Nav Destination
Favorable effect of priming with granulocyte colony-stimulating factor in remission induction of acute myeloid leukemia restricted to dose escalation of cytarabine
Prospective study of rabbit antithymocyte globulin and cyclosporine for aplastic anemia from the EBMT Severe Aplastic Anaemia Working Party
Effects of induction and maintenance plus long-term bisphosphonates on bone disease in patients with multiple myeloma: the Medical Research Council Myeloma IX Trial
A phase 1/2 study of lenalidomide with low-dose oral cyclophosphamide and low-dose dexamethasone (RdC) in AL amyloidosis
Activity of pomalidomide in patients with immunoglobulin light-chain amyloidosis
The superiority of haploidentical related stem cell transplantation over chemotherapy alone as postremission treatment for patients with intermediate- or high-risk acute myeloid leukemia in first complete remission
Reduced-intensity conditioning transplantation in acute leukemia: the effect of source of unrelated donor stem cells on outcomes
Issue Archive
June 7 2012
In this Issue
Table of Contents
Inside Blood
Blood Work
Perspectives
Review Article
Clinical Trials and Observations
Favorable effect of priming with granulocyte colony-stimulating factor in remission induction of acute myeloid leukemia restricted to dose escalation of cytarabine
Clinical Trials & Observations
Thomas Pabst,for the Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON),Edo Vellenga,for the Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON),Wim van Putten,for the Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON),Harry C. Schouten,for the Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON),Carlos Graux,for the Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON),Marie-Christiane Vekemans,for the Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON),Bart Biemond,for the Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON),Peter Sonneveld,for the Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON),Jakob Passweg,for the Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON),Leo Verdonck,for the Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON),Marie-Cecile Legdeur,for the Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON),Matthias Theobald,for the Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON),Emanuel Jacky,for the Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON),Mario Bargetzi,for the Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON),Johan Maertens,for the Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON),Gert Jan Ossenkoppele,for the Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON),Bob Löwenberg,for the Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON)
Hematopoiesis and Stem Cells
Prospective study of rabbit antithymocyte globulin and cyclosporine for aplastic anemia from the EBMT Severe Aplastic Anaemia Working Party
Clinical Trials & Observations
Judith C. Marsh,on behalf of the European Blood and Marrow Transplant Group Severe Aplastic Anaemia Working Party,Andrea Bacigalupo,on behalf of the European Blood and Marrow Transplant Group Severe Aplastic Anaemia Working Party,Hubert Schrezenmeier,on behalf of the European Blood and Marrow Transplant Group Severe Aplastic Anaemia Working Party,Andre Tichelli,on behalf of the European Blood and Marrow Transplant Group Severe Aplastic Anaemia Working Party,Antonio M. Risitano,on behalf of the European Blood and Marrow Transplant Group Severe Aplastic Anaemia Working Party,Jakob R. Passweg,on behalf of the European Blood and Marrow Transplant Group Severe Aplastic Anaemia Working Party,Sally B. Killick,on behalf of the European Blood and Marrow Transplant Group Severe Aplastic Anaemia Working Party,Alan J. Warren,on behalf of the European Blood and Marrow Transplant Group Severe Aplastic Anaemia Working Party,Theodora Foukaneli,on behalf of the European Blood and Marrow Transplant Group Severe Aplastic Anaemia Working Party,Mahmoud Aljurf,on behalf of the European Blood and Marrow Transplant Group Severe Aplastic Anaemia Working Party,H. A. Al-Zahrani,on behalf of the European Blood and Marrow Transplant Group Severe Aplastic Anaemia Working Party,Philip Schafhausen,on behalf of the European Blood and Marrow Transplant Group Severe Aplastic Anaemia Working Party,Alexander Roth,on behalf of the European Blood and Marrow Transplant Group Severe Aplastic Anaemia Working Party,Anke Franzke,on behalf of the European Blood and Marrow Transplant Group Severe Aplastic Anaemia Working Party,Tim H. Brummendorf,on behalf of the European Blood and Marrow Transplant Group Severe Aplastic Anaemia Working Party,Carlo Dufour,on behalf of the European Blood and Marrow Transplant Group Severe Aplastic Anaemia Working Party,Rosi Oneto,on behalf of the European Blood and Marrow Transplant Group Severe Aplastic Anaemia Working Party,Philip Sedgwick,on behalf of the European Blood and Marrow Transplant Group Severe Aplastic Anaemia Working Party,Alain Barrois,on behalf of the European Blood and Marrow Transplant Group Severe Aplastic Anaemia Working Party,Shahram Kordasti,on behalf of the European Blood and Marrow Transplant Group Severe Aplastic Anaemia Working Party,Modupe O. Elebute,on behalf of the European Blood and Marrow Transplant Group Severe Aplastic Anaemia Working Party,Ghulam J. Mufti,on behalf of the European Blood and Marrow Transplant Group Severe Aplastic Anaemia Working Party,Gerard Socie,on behalf of the European Blood and Marrow Transplant Group Severe Aplastic Anaemia Working Party
MT1-MMP plays a critical role in hematopoiesis by regulating HIF-mediated chemokine/cytokine gene transcription within niche cells
Chiemi Nishida,Kaori Kusubata,Yoshihiko Tashiro,Ismael Gritli,Aki Sato,Makiko Ohki-Koizumi,Yohei Morita,Makoto Nagano,Takeharu Sakamoto,Naohiko Koshikawa,Takahiro Kuchimaru,Shinae Kizaka-Kondoh,Motoharu Seiki,Hiromitsu Nakauchi,Beate Heissig,Koichi Hattori
Overcoming reprogramming resistance of Fanconi anemia cells
Lars U. W. Müller,Michael D. Milsom,Chad E. Harris,Rutesh Vyas,Kristina M. Brumme,Kalindi Parmar,Lisa A. Moreau,Axel Schambach,In-Hyun Park,Wendy B. London,Kelly Strait,Thorsten Schlaeger,Alexander L. DeVine,Elke Grassman,Alan D'Andrea,George Q. Daley,David A. Williams
Immunobiology
Frequent somatic mosaicism of NEMO in T cells of patients with X-linked anhidrotic ectodermal dysplasia with immunodeficiency
Tomoki Kawai,Ryuta Nishikomori,Kazushi Izawa,Yuuki Murata,Naoko Tanaka,Hidemasa Sakai,Megumu Saito,Takahiro Yasumi,Yuki Takaoka,Tatsutoshi Nakahata,Tomoyuki Mizukami,Hiroyuki Nunoi,Yuki Kiyohara,Atsushi Yoden,Takuji Murata,Shinya Sasaki,Etsuro Ito,Hiroshi Akutagawa,Toshinao Kawai,Chihaya Imai,Satoshi Okada,Masao Kobayashi,Toshio Heike
Lymphoid Neoplasia
Effects of induction and maintenance plus long-term bisphosphonates on bone disease in patients with multiple myeloma: the Medical Research Council Myeloma IX Trial
Clinical Trials & Observations
Gareth J. Morgan,on behalf of the National Cancer Research Institute Haematological Oncology Clinical Studies Group,Faith E. Davies,on behalf of the National Cancer Research Institute Haematological Oncology Clinical Studies Group,Walter M. Gregory,on behalf of the National Cancer Research Institute Haematological Oncology Clinical Studies Group,Alex J. Szubert,on behalf of the National Cancer Research Institute Haematological Oncology Clinical Studies Group,Sue E. Bell,on behalf of the National Cancer Research Institute Haematological Oncology Clinical Studies Group,Mark T. Drayson,on behalf of the National Cancer Research Institute Haematological Oncology Clinical Studies Group,Roger G. Owen,on behalf of the National Cancer Research Institute Haematological Oncology Clinical Studies Group,A. John Ashcroft,on behalf of the National Cancer Research Institute Haematological Oncology Clinical Studies Group,Graham H. Jackson,on behalf of the National Cancer Research Institute Haematological Oncology Clinical Studies Group,J. Anthony Child,on behalf of the National Cancer Research Institute Haematological Oncology Clinical Studies Group
A phase 1/2 study of lenalidomide with low-dose oral cyclophosphamide and low-dose dexamethasone (RdC) in AL amyloidosis
Clinical Trials & Observations
Efstathios Kastritis,Evangelos Terpos,Maria Roussou,Maria Gavriatopoulou,Constantinos Pamboukas,Ioannis Boletis,Smaragda Marinaki,Theofanis Apostolou,Nikitas Nikitas,Georgios Gkortzolidis,Eurydiki Michalis,Sossana Delimpasi,Meletios A. Dimopoulos
Activity of pomalidomide in patients with immunoglobulin light-chain amyloidosis
Clinical Trials & Observations
Angela Dispenzieri,Francis Buadi,Kristina Laumann,Betsy LaPlant,Suzanne R. Hayman,Shaji K. Kumar,David Dingli,Steven R. Zeldenrust,Joseph R. Mikhael,Robert Hall,S. Vincent Rajkumar,Craig Reeder,Rafael Fonseca,P. Lief Bergsagel,A. Keith Stewart,Vivek Roy,Thomas E. Witzig,John A. Lust,Stephen J. Russell,Morie A. Gertz,Martha Q. Lacy
Identification of LMO2 transcriptome and interactome in diffuse large B-cell lymphoma
Elena Cubedo,Andrew J. Gentles,Chuanxin Huang,Yasodha Natkunam,Shruti Bhatt,Xiaoqing Lu,Xiaoyu Jiang,Isabel Romero-Camarero,Aharon Freud,Shuchun Zhao,Carlos E. Bacchi,Jose A. Martínez-Climent,Isidro Sánchez-García,Ari Melnick,Izidore S. Lossos
Myeloid Neoplasia
Cyclin-A1 represents a new immunogenic targetable antigen expressed in acute myeloid leukemia stem cells with characteristics of a cancer-testis antigen
Sebastian Ochsenreither,Ravindra Majeti,Thomas Schmitt,Derek Stirewalt,Ulrich Keilholz,Keith R. Loeb,Brent Wood,Yongiae E. Choi,Marie Bleakley,Edus H. Warren,Michael Hudecek,Yoshiki Akatsuka,Irving L. Weissman,Philip D. Greenberg
Phagocytes, Granulocytes, and Myelopoiesis
Red Cells, Iron, and Erythropoiesis
Thrombosis and Hemostasis
Tumor-derived tissue factor activates coagulation and enhances thrombosis in a mouse xenograft model of human pancreatic cancer
Jian-Guo Wang,Julia E. Geddings,Maria M. Aleman,Jessica C. Cardenas,Pichika Chantrathammachart,Julie C. Williams,Daniel Kirchhofer,Vladimir Y. Bogdanov,Ronald R. Bach,Janusz Rak,Frank C. Church,Alisa S. Wolberg,Rafal Pawlinski,Nigel S. Key,Jen Jen Yeh,Nigel Mackman
Transfusion Medicine
Transplantation
The superiority of haploidentical related stem cell transplantation over chemotherapy alone as postremission treatment for patients with intermediate- or high-risk acute myeloid leukemia in first complete remission
Clinical Trials & Observations
Xiao-Jun Huang,Hong-Hu Zhu,Ying-Jun Chang,Lan-Ping Xu,Dai-Hong Liu,Xiao-Hui Zhang,Bin Jiang,Qian Jiang,Hao Jiang,Yu-Hong Chen,Huan Chen,Wei Han,Kai-Yan Liu,Yu Wang
Reduced-intensity conditioning transplantation in acute leukemia: the effect of source of unrelated donor stem cells on outcomes
Clinical Trials & Observations
Claudio G. Brunstein,Mary Eapen,Kwang Woo Ahn,Frederick R. Appelbaum,Karen K. Ballen,Richard E. Champlin,Corey Cutler,Fangyu Kan,Mary J. Laughlin,Robert J. Soiffer,Daniel J. Weisdorf,Anne Woolfrey,John E. Wagner
Vascular Biology
-
Cover Image
Cover Image
The photomicrographs depict hematopoietic cells derived from gene-corrected Fanconi anemia patient-specific induced pluripotent stem cells (iPSCs). To effect hematopoietic differentiation, iPSC lines were allowed to aggregate to embryoid bodies. After 15 days, the embryoid bodies were disaggregated and seeded in hematopoietic growth factor–containing semisolid methylcellulose. Cytospins of individual colonies were stained with Wright-Giemsa and photographed at 60× magnification. See the article by Müller et al on page 5449.
- PDF Icon PDF LinkFront Matter
- PDF Icon PDF LinkTable of Contents
- PDF Icon PDF LinkBack Matter
- PDF Icon PDF LinkAdvertising
- PDF Icon PDF LinkEditorial Board
Advertisement intended for health care professionals
Email alerts
Advertisement intended for health care professionals